Immatics stock in focus

Immatics (NasdaqCM:IMTX) is drawing attention after recent share price moves, with the stock last closing at US$11.14 and showing positive total returns over the past year and the past 3 months.

Recent moves fit a bigger pattern, with a 30 day share price return of 8.68% and a 90 day share price return of 15.68%, alongside a very large 1 year total shareholder return of 156.68%. These figures point to building momentum.

If you are looking beyond a single biotech stock, this could be a good moment to scan for other opportunities in healthcare related AI, starting with 35 healthcare AI stocks

With Immatics posting a very large 1 year return and trading at US$11.14 against an analyst price target of US$18.75, readers may be wondering if there is still a buying opportunity or if the current market price already reflects expectations for future growth.

Preferred Price-to-Sales Multiple of 26.4x: Is it justified?

Immatics trades on a P/S of 26.4x, which is high against both its biotech peers and an estimated fair level, so the current valuation looks demanding at $11.14.

The P/S ratio compares the company’s market value to its revenue. A higher multiple typically reflects strong expectations for future sales or a willingness to pay up for exposure to a specific pipeline. For a clinical stage biotech that is still loss making, P/S is often used because earnings are negative and traditional profit based metrics are not yet meaningful.

In Immatics’ case, the stock is described as expensive on this measure compared with the US Biotechs industry average P/S of 10.9x and a peer average of 23.6x. Against an estimated fair P/S ratio of just 0.1x, the current level stands out as especially rich, setting a high bar for the company’s T cell immunotherapy pipeline to justify over time.

Result: Price-to-Sales of 26.4x (OVERVALUED)

However, the story can shift quickly if clinical trial outcomes disappoint or if the company’s US$196.447 million net loss leads to funding pressure at current valuations.

Next Steps

With sentiment clearly mixed, this is a moment to move quickly. Review the numbers for yourself and weigh both the upside and the warning signs in the 1 key reward and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you may miss chances elsewhere. Use the screener to quickly spot other opportunities that fit your style.

• Target companies that look mispriced by the market and see which ones stand out using the 51 high quality undervalued stocks.
• Prioritize resilience and focus on businesses that score well on financial strength through the solid balance sheet and fundamentals stocks screener (44 results).
• Hunt for lesser known opportunities with strong fundamentals before they gain wider attention by checking the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.